Recurrent Glioblastoma Clinical Trials

38 recruiting

Frequently Asked Questions

Common questions about Recurrent Glioblastoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 45 trials

Recruiting
Phase 2

Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma

Recurrent GlioblastomaProgressive Glioblastoma
National Cancer Institute (NCI)184 enrolled317 locationsNCT06325683
Recruiting
Phase 1

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

Astrocytoma, IDH-Mutant, Grade 2Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-MutantRecurrent Adult Diffuse Midline Glioma, H3 K27-Mutant+4 more
National Cancer Institute (NCI)30 enrolled41 locationsNCT06860594
Recruiting
Phase 1

Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma

GliomaRecurrent GlioblastomaAstrocytoma
National Cancer Institute (NCI)28 enrolled1 locationNCT06344130
Recruiting
Phase 1

Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma

GlioblastomaMalignant GliomaRecurrent Glioblastoma+2 more
Beijing Biotech36 enrolled1 locationNCT07480941
Recruiting
Phase 1

Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells

GlioblastomaEGFR Gene MutationMGMT-Unmethylated Glioblastoma+1 more
Hideho Okada, MD, PhD20 enrolled1 locationNCT06186401
Recruiting
Phase 2

A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma

Recurrent Glioblastoma
BioNTech SE75 enrolled1 locationNCT07297212
Recruiting
Phase 1

CUE-102 in Recurrent Glioblastoma

GlioblastomaGlioma, MalignantRecurrent Glioblastoma
David Reardon, MD18 enrolled2 locationsNCT06917885
Recruiting
Phase 1

MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma

Recurrent GlioblastomaRecurrent Malignant GliomaRecurrent Gliosarcoma+2 more
M.D. Anderson Cancer Center36 enrolled1 locationNCT03896568
Recruiting
Phase 2

Surgical Pembro +/- Olaparib w TMZ for rGBM

GlioblastomaRecurrent Glioblastoma
L. Nicolas Gonzalez Castro, MD, PhD78 enrolled4 locationsNCT05463848
Recruiting
Phase 1

A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM

Glioblastoma MultiformeRecurrent Glioblastoma
Boston Scientific Corporation36 enrolled9 locationsNCT05303467
Recruiting
Phase 2

Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer

Metastatic CancerLeptomeningeal MetastasisBrain Cancer+2 more
Memorial Sloan Kettering Cancer Center30 enrolled1 locationNCT06058988
Recruiting
Early Phase 1

Sonodynamic Therapy With SONALA-001 or 5-ALA HCL and Magnetic Resonance Guided Focused Ultrasound for the Treatment of Progressive or Recurrent Glioblastoma

Recurrent GlioblastomaProgressive Glioblastoma
Mayo Clinic8 enrolled1 locationNCT07076472
Recruiting
Phase 1Phase 2

A Clinical Trial of P134 Cells in Recurrent Glioblastoma

Recurrent Glioblastoma, IDH-Wildtype
Tasly Pharmaceutical Group Co., Ltd26 enrolled1 locationNCT07318818
Recruiting
Phase 1

CARv3-TEAM-E T Cells in Glioblastoma

GlioblastomaMalignant GliomaRecurrent Glioblastoma+1 more
Marcela V. Maus, M.D.,Ph.D.21 enrolled1 locationNCT05660369
Recruiting
Phase 2

Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

Recurrent Glioblastoma, IDH-WildtypeRecurrent GliosarcomaHigh Grade Astrocytic Tumor
Mayo Clinic54 enrolled1 locationNCT05465954
Recruiting
Phase 2

OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial

Recurrent Glioblastoma
University of Florida20 enrolled1 locationNCT06558214
Recruiting
Phase 1

A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

Recurrent Glioblastoma MultiformePrimary Glioblastoma MultiformeBrain Neoplasms, Malignant+1 more
AstraZeneca180 enrolled12 locationsNCT03423628
Recruiting
Phase 1Phase 2

Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma

Recurrent GlioblastomaRecurrent Gliosarcoma
M.D. Anderson Cancer Center6 enrolled1 locationNCT05039281
Recruiting
Phase 1

Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM

Recurrent Glioblastoma
University of Pennsylvania12 enrolled1 locationNCT07209241
Recruiting
Not Applicable

A Study to Assess the Feasibility and Safety of Intratumoral Diffusing Alpha Emitters for the Treatment of Recurrent Glioblastoma

Recurrent GlioblastomaRecurrent Gliomas
Alpha Tau Medical LTD.10 enrolled1 locationNCT06910306